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Introduction: Safe driving requires integration of higher-order cognitive and motor
functions, which are commonly compromised in patients with antibody-mediated
encephalitis (AME) associated with N-methyl-D-aspartate receptors or leucine-rich
glioma-inactivated 1 autoantibodies. How these deficits influence the return to safe
driving is largely unknown. Recognizing this, we piloted non-invasive remote monitoring
technology to longitudinally assess driving behaviors in recovering AME patients.
Methods: Five recovering AME patients [median age, 52 years (range 29–67); two
females] were recruited from tertiary care clinics at Washington University (St. Louis, MO).
Trip data and aggressive actions (e.g., hard braking, sudden acceleration, speeding) were
continuously recorded using a commercial Global Positioning System data logger when
the patient’s vehicle was driven by the designated driver. Longitudinal driving data were
compared between AME patients and cognitively normal older adults (2:1 sex-matched)
enrolled within parallel studies.
Results: Driving behaviors were continuously monitored for a median of 29 months
(range, 21–32). AME patients took fewer daily trips during the last vs. the first 6 months
of observation, with a greater proportion of trips exceeding 10 miles. Compared to
cognitively normal individuals, AME patients were more likely to experience hard braking
events as recovery progressed. Despite this, no accidents were self-reported or captured
by the data logger.
Conclusion: Driving behaviors can be continuously monitored in AME patients using
non-invasive means for protracted periods. Longitudinal changes in driving behavior may
parallel functional recovery, warranting further study in expanded cohorts of recovering
AME patients.
Keywords: autoimmune, antibody-mediated, encephalitis, N-methyl-D-aspartate (NMDA) receptor, LGI1,
autoantibodies, driving
INTRODUCTION
Antibody-mediated encephalitides (AMEs) are a group of increasingly prevalent inflammatory
brain disorders that result from antibody-mediated disruption of neuronal cell surface proteins,
receptors, or ion channels. AME commonly presents with changes in behavior, psychosis, seizures,
memory and cognitive deficits, abnormalmovements, dysautonomia, and changes in consciousness
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(1). Although the potential for meaningful recovery is high in
patients who receive early treatment with immunosuppressant
agents (1–5), impairments in memory and executive function
are well-recognized complications of AME (4, 6–9). How these
deficits influence the return to meaningful function in recovering
patients is largely unknown, as is the time course and extent of
recovery of higher-order function.
Driving is an instrumental activity of daily living that
is integral to patient-perceived independence, well-being,
autonomy, and quality of life (10, 11). Conversely, forced
driving cessation is associated with increased depressive
symptomatology, higher rates of admission to institutional care,
and social isolation (12, 13). For these reasons, the return to safe
driving is a shared priority between patients and their providers.
Safe driving requires integration of higher-order cognitive
and motor functions, drawing upon heteromodal (association)
and unimodal (sensory/motor) cortices and relying heavily on
sound judgment and decision-making. Accordingly, changes
in driving behavior may provide a real-world correlate for
changes in higher-order function associated with neurological
diseases (14, 15). Recovering AME patients may experience
greater risks following the return to driving due to persistent
frontal-executive and memory dysfunction (7, 8). However, little
guidance is available to direct clinical recommendations on the
return to driving in recovering AME patients.
Recent advances in Global Positioning System (GPS)
technology have enabled passive collection of driving data
from individuals operating their personal vehicles in their
native environments. These advances allow the relationship
between longitudinal changes in driving behaviors and
higher-order functions to be assessed, with the potential
that measures of naturalistic driving behaviors may inform
the time course and extent of recovery in AME patients.
We leveraged available technology to assess the feasibility of
capturing driving behavior over time in a small cohort of
patients returning to driving following treatment for AME
associated with autoantibodies against N-methyl-D-aspartate




Registrations, and Patient Consents
Patients were enrolled from January to October 2017 within
prospective studies permitting longitudinal collection and
monitoring of clinical symptoms and signs in recovering AME
patients. Written informed consent was obtained from all
individuals or their delegates, allowing the collection of relevant
clinical information and installation and remote monitoring
of driving behaviors using a commercial-off-the-shelf GPS
data logger together with naturalistic driving methodology
(15, 16)—termed the Driving Real World In-Vehicle
Evaluation System [DRIVES (17)]. The Washington University
School of Medicine Institutional Review Board approved all
study procedures.
Participant Selection, Evaluation, and
Follow-Up
Patients with AME were admitted to study hospitals and
thoroughly evaluated by experienced clinicians. All patients
met the criteria for definite AME, including presentation
with the subacute-onset of memory deficits, mental status
change, or psychiatric symptoms, with at least one of new
focal central nervous system findings, unexplained seizures,
cerebrospinal fluid (CSF) pleocytosis, or MRI features suggestive
of encephalitis. Immunoglobulin G (IgG) autoantibodies were
identified against central nervous system NMDAR in the
CSF or LGI1 receptors in the CSF or serum, and alternate
causes of impairment were excluded (18). Antibody testing was
performed at the Mayo Clinic Neuroimmunology Laboratory
(Rochester, Minnesota) using indirect immunofluorescence
(specimen applied to frozen mouse composite tissue, washed
and treated with fluorescein-conjugated IgG), cell binding,
Western blot, and radioimmune assays. Investigations and
immunomodulatory treatments were prescribed by treating
physicians in accordance with clinical indications. Outpatient
follow-up was provided via the Washington University
Rapidly Progressive Dementia Clinic. Cognitive functions
were prospectively assessed at clinical visits with the global
Clinical Dementia Rating (CDR)—a widely used, validated,
and reproducible measure of cognitive function (19)—and
standardized bedside measures of global cognitive function,
including the Montreal Cognitive Assessment [MoCA (20)]
and Mini-Mental State Examination [MMSE (21)]. Disability
was assessed using the modified Rankin scale [mRS (22)]—a
common outcome measure in AME (2, 3, 5). All participants
completed the Trails A and B tasks, recognizing that performance
on these measures may predict performance on on-road driving
assessments (23).
Community-dwelling cognitively normal (CN) participants (n
= 10; 2:1 sex-matched; median age = 68 years, range 65–70)
were recruited from longitudinal studies of memory and aging at
the Washington University Knight Alzheimer Disease Research
Center (St. Louis, MO). Clinical and neuropsychological
assessments were completed as previously described (15, 24).
All participants were CN [global CDR = 0 (19)], had a
valid driver’s license, and reported driving at least once
per week.
Measurement of Naturalistic Driving
Behaviors
All patients reported ≥5 years of pre-illness on-road driving
experience, maintained an active driver’s license, and were
cleared to return to driving by their treating neurologist,
referencing prevailing laws. No patient had electrographically
confirmed seizures in the hospital. Prior to the return to driving, a
commercial-off-the-shelf GPS data logger (DRIVES; G2 Tracking
DeviceTM, Azuga Inc., San Jose, CA) was plugged into the
participant’s vehicle’s onboard diagnostics-II (OBD-II) port.
Within 1min of installation, the chip accessed available satellites
for orientation and synchronization and began transmitting
data to servers in San Jose (CA) via Bluetooth Low Energy
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using available cell phone towers. Data were aggregated daily
by the vendor and made available for download via secured
servers. Study participants (AME patients and CN individuals)
agreed to carry a credit card-sized Bluetooth Low Energy
device (Azuga Inc., San Jose, CA) in their wallet or purse.
This device automatically paired with the chip when the
participant was in the driver’s seat, identifying the participant as
the driver.
Using the DRIVES methodology, data were collected every
30 s while the vehicle was driven by the study participant,
recording date and time, latitude, longitude, odometer reading,
speed, and event type (16). Vehicle speed was compared to
the posted speed limit in a given region. “Speeding” events
were encoded whenever vehicle speed exceeded the posted
limit by 6 miles per hour. Rapid changes in vehicle speed
were recorded as hard braking or sudden acceleration events
(16). These “aggressive driving” events (speeding, hard braking,
sudden acceleration) were recorded anytime they occurred
during a trip, regardless of the data sampling interval. Trip
data were also captured, including trip date and start time,
starting and ending locations, the duration in seconds and
length of the trip, the mean and maximum vehicle speeds,
and the number of aggressive driving events. A “trip” was
defined from the period of “ignition on” to “ignition off”
(e.g., a return excursion to the grocery store without any
other stops would be considered two trips). Data logger data
were aggregated by month, so that an individual followed
for 1 year would have 12 data points across time for
each variable.
Statistical Analyses
Data were collected and managed securely using a research
electronic data capture tool [REDCap (25)]. Individual
performance on standardized cognitive tests were compared
with expected performance derived from age- and education-
matched normative data for the MoCA (20), MMSE (26), and
Trails A/B tasks (23). Briefly, Z-scores were calculated on a
test-by-test basis by subtracting the reported population mean
from the patient’s raw score and dividing the difference by the
population standard deviation. P-values were inferred from the
standard normal distribution, with p < 0.05 deemed significant.
Driving behaviors in AME patients were dichotomized,
comparing between “early” (first 6 months following the return
to driving) and “late” (last 6 months of observation) periods
using the S-statistic. Differences in longitudinal driving behaviors
between AME patients and CN individuals were quantified using
univariate linear mixed models, querying the interaction
between cohort and the week number. A more permissive
p-value was selected (p < 0.1) for population comparisons,
given the exploratory nature of these analyses in a small cohort
of AME patients. Statistical analyses were conducted in SAS
version 9.4 (SAS Institute, Cary, NC), while data analysis and
management for spatial operations used ArcGIS 10.3.1 and the
ArcPy Python site package (Environmental Systems Research
Institute, Redlands, CA).
RESULTS
Driving behaviors were assessed in five recovering AME patients
[median age, 52 years (range 29–67); two females]. Demographic,
clinical characteristics, and results of investigations and
treatments are detailed in Table 1. All patients met diagnostic
criteria for definite AME (18), with presentations and clinical
courses consistent with AME associated with NMDAR (18)
or LGI1 (3) autoantibodies. Maximal illness severity ranged
from mild (mRS ≤ 2; e.g., Case C) to severe (mRS = 5; Case
A). No patient had a disease-associated tumor. First-line
immunotherapies, including high-dose methylprednisolone [1 g
intravenously (IV) over 5 days] or intravenous immunoglobulin
(2 g/kg over 5 days), were provided to all patients within 1 week
of hospital admission. Two patients with persistent impairment
were additionally treated with rituximab (375 mg/m2 IV weekly
× 4). Patients with AME associated with autoantibodies against
LGI1 antigens were continued on oral steroids (1 mg/kg daily)
upon hospital discharge, with the dosage tapered over 3 months.
Recovering AME patients returned to driving a median of
5.7 (range, 1–16) weeks following admission to the hospital
(34 weeks from symptom onset, range 12–68), by which time
all patients had “good” motor outcomes, defined as mRS ≤ 2.
Cognitive function and processing speed were further assessed
using the global CDR and bedside measures (Table 2). Patients
with AME associated with LGI1 autoantibodies had very mild
impairment in cognitive function (CDR = 0.5); patients with
NMDAR autoantibodies were CN (CDR = 0). Performance on
the MoCA was substantially lower than expected for age and
education in 3/5 (60%) of AME patients (Z ≤ −1.96; p < 0.05).
Only Case D exhibited impairment on the MMSE (Z = −2.3;
p = 0.02). All patients completed the Trails A task as expected.
Cases C (Z =−3.6; p < 0.001) and E (Z =−5.6; p < 0.001) were
substantially slower in completing Trails B.
Driving behaviors were monitored for a median of 29
months (range, 21–32). No accidents were reported by
study participants or captured by the DRIVES. Compared
to the initial 6 months following the return to driving,
AME patients took fewer daily trips in the last 6 months
of observation, with an increased tendency to take longer
trips (≥10 miles; Table 3). No differences were observed in
the relative frequency of behaviors associated with aggressive
driving in the early and late observation periods. When
longitudinal driving behaviors were compared between AME
patients and a 2:1 sex-matched cohort of older CN individuals,
recovering AME patients experienced more hard braking
events per trip with weeks from recovery (slope = 0.18 ±
0.07), while CN individuals experienced fewer events (slope
= −0.003 ± 0.04; p = 0.08; Table 4). No differences were
observed in other driving behaviors between AME patients and
CN individuals.
Patients were reassessed a median of 16.4 weeks (range,
3–69) following the return to driving [median 57.4 weeks
(range, 17–86) from symptom onset], by which time all
patients had successfully returned to prior vocational or
educational function and had tapered off immunotherapies.
The global CDR was 0 (CN) in all patients, except for Case
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TABLE 1 | Demographic features, clinical presentation, investigations, and treatments in AME patients.
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30 NA 3 3 3
C/37M Memory loss,
painful paresthesias
No focal deficits 9 Normal LGI1
(serum)



















40 NA 1 2 2
AME, antibody-mediated encephalitis; AMS, altered mental status; CSF, cerebrospinal fluid; FLAIR, fluid-attenuated inversion recovery; gCDR, global Clinical Dementia Rating (19);
IVIg, intravenous immunoglobulin (0.4 g/kg × 5 days); LGI1, leucine-rich glioma-inactivated 1; MRI, magnetic resonance imaging; mRS, modified Rankin scale (22); NMDAR, N-
methyl-D-aspartate receptor; PLEX, plasmapheresis/plasma exchange (10 treatments); rituximab, 375 mg/m2 IV × 4 weeks; steroids, intravenous methylprednisolone (1 g per day ×
5 days).
†Age at DRIVES install.
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Z-scores for neuropsychological testing were calculated by comparing raw scores to age- and education-matched norms. Z-scores were calculated on a test-by-test basis by subtracting
the reported population mean from the patient’s raw score and dividing the difference by the population standard deviation. Negative Z-scores reflect worse-than-expected patient
performance; positive Z-scores reflect better-than-expected patient performance. P-values were inferred from the standard normal distribution. P values < 0.05 are bolded.
Trail Making Tests A and B are scored in seconds [higher values indicate worse performance (23)].
AME, antibody-mediated encephalitis; gCDR, global Clinical Dementia Rating (19); MMSE, Mini-Mental State Examination (21, 26); MoCA, Montreal Cognitive Assessment (20); mRS,
modified Rankin scale (22); NA, not available (test not performed).
C who complained of isolated short-term memory deficits
(CDR 0.5, memory only). The mRS ranged from 0 to 1
(median = 1). Cognitive testing was completed in four of
five patients (omitted in Case D), with improvement noted
in all domains in all patients. Performance on the Trails
B test remained slower than expected in two, Cases C
(Z = −2.6, p < 0.01) and E (Z = −3.9, p < 0.001);
otherwise, performance was within the range expected for age
and education.
DISCUSSION
Frontal-executive and memory dysfunction are well-recognized
complications of AME associated with NMDAR and LGI1
autoantibodies, with deficits attributed to changes in the density
of cell surface receptors (27–29), brain structure (7, 30), and
network integrity (7, 8, 31–33). Although these changes may
be reversible, the time course and extent over which recovery
occurs are largely unknown. Safe driving requires continuous
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TABLE 3 | Early and late driving behaviors in AME patients.
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AME, antibody-mediated encephalitis; SD, standard deviation.
Comparisons where p < 0.1 are bolded.
integration of complex cognitive and motor functions that are
widely distributed throughout the brain (34, 35). It is not
surprising, therefore, that dynamic changes in driving behaviors
were observed in the small cohort of AME patients included in
this pilot study.
The tendency to take more frequent, shorter trips upon the
return to driving may reflect self-regulation by AME patients—
referring to the process whereby drivers intentionally avoid
driving in situations considered to be challenging [e.g., long
travel, driving within congested urban areas or on freeways
(36)]. When aptly deployed, these adaptive strategies may extend
the duration over which individuals may drive safely and
maintain independence (37, 38). Detection of these changes
may identify individuals at-risk for brain pathology that may
compromise driving ability. In a longitudinal study measuring
objective driving behaviors in older CN community-dwelling
adults, drivers with early (i.e., “preclinical”) brain changes related
to Alzheimer disease exhibited decreased driving space and
exposure and had a lower number of trips with “aggressive
behaviors” (especially hard braking and sudden acceleration)
than their Alzheimer disease-free counterparts (15). In contrast
to patients with neurodegenerative diseases, the cognitive and
motor deficits associated with AME may resolve with time from
treatment. Consistent with this, recovering AME patients were
more likely to take longer trips with more frequent hard braking
episodes later in the recovery period. These changes could
suggest increasing risky or aggressive behaviors. Alternatively,
the emergence of hard braking episodes in recovering patients
taking longer trips may reflect progressive normalization of
driving behaviors in patients returning to professional and
personal routines. This may include travel within urban centers
and other areas (e.g., shopping centers, parking lots) where hard
braking may be required to prevent accidents while navigating
amid higher-density traffic.
Although preliminary, these results suggest that DRIVES
may be used to measure functional recovery—not just decline.
Access to an objective and dynamic measure of driving
safety would convey substantial advantages over existing time-
consuming and costly approaches used to assess driving safety,
including direct observation of driving behaviors in structured
or simulated environments (14, 35, 39, 40). If validated in
larger numbers of patients, DRIVES may permit continuous,
non-invasive, and objective measurement of complex cognitive
and motor behaviors across protracted periods of time. In
turn, these findings may inform the timeline for the safe
return to driving in AME patients; facilitate evaluation of
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TABLE 4 | Slopes of linear mixed models describing the interaction between



























































































AME, antibody-mediated encephalitis; CN, cognitively normal; SE, standard error.
Comparisons where p < 0.1 are bolded.
modifiable patient-, disease-, and treatment-specific factors
that associate with recovery; and inform the association
between driving behaviors and neurologic sequelae in recovering
AME patients.
The interpretation of study findings is limited by the small
number of patients enrolled in this pilot study conducted
at a single academic medical center. Findings need to be
validated in larger numbers of patients with AME associated
with autoantibodies against NMDAR, LGI1, and other antigens,
acknowledging the broad variability in the clinical phenotype and
long-term outcomes in AME (1–6, 9) and the low likelihood
of detecting rare events (i.e., motor vehicle accidents) in small
cohorts of patients. Future studies would also benefit from
recruitment of age-matched comparison cohorts. As older age
is associated with increasing age performance inconsistencies
(41), the use of a convenience cohort comprised of older CN
individuals may have decreased the ability to detect longitudinal
differences between AME patients and CN individuals in this
study. Non-invasive monitoring was performed across prolonged
periods of time to minimize the contributions of observation bias
to the results of this pilot study. However, it is possible that AME
patients modified driving behaviors in response to monitoring.
The effect of monitoring could be evaluated through future
studies that vary the degree of invasive monitoring. Integration
of additional tools that permit recording of the driver’s field of
view would also allow direct evaluation of “near misses” and
other risky behaviors in recovering patients, as well as other
environmental factors that may influence driving performance
(e.g., presence or absence of passengers, use of radio). Such tools
may assist with determining whether trends in behavior (e.g.,
hard braking events) represent defensive maneuvers executed
by drivers commuting to work in congested urban areas (a
correlate for functional improvement or normalization of driving
behaviors) or unsafe behaviors observed in distracted drivers (a
correlate for persistent dysfunction).
Limitations notwithstanding, the DRIVES provided robust
information on driving behaviors in a small cohort of
recovering AME patients. These results suggest that driving
behaviors in AME patients can be continuously monitored
using non-invasive means across protracted periods of time.
Longitudinal changes in driving behavior may parallel functional
recovery in AME, warranting further study in expanded
cohorts of patients who have been approved to return to
driving by their treating physicians, referencing prevailing laws
and recommendations.
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